Stifel Nicolaus analyst Paul Matteis has maintained their bullish stance on KALV stock, giving a Buy rating yesterday.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Paul Matteis has given his Buy rating due to a combination of factors that highlight KalVista Pharmaceuticals’ strategic position in the market. Despite the competitive landscape, KalVista has successfully captured approximately 10% of the U.S. hereditary angioedema (HAE) market shortly after its product launch, demonstrating strong market penetration and favorable feedback from both patients and physicians.
Moreover, while competitor PHVS has shown promising results with its product deucrictibant, the nuances in trial comparisons and the existing market presence of KalVista suggest that significant patient switching from Ekterly to deucrictibant may not be immediate. KalVista’s established market foothold, combined with the time advantage before PHVS’s potential entry, positions it well to further solidify its market share. These elements contribute to Matteis’s optimistic outlook on KalVista’s stock, warranting a Buy recommendation.
In another report released yesterday, Needham also maintained a Buy rating on the stock with a $28.00 price target.